Phoenix Heart PLLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$71,605	2
2021	Research	$8,806	1
2020	Research	$31,493	5
2019	Research	$45,463	4

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $80,623 3 payments
Impulse Dynamics (USA) Inc. $71,605 2 payments
Bayer HealthCare Pharmaceuticals Inc. $3,779 4 payments
Boston Scientific Corporation $1,360 3 payments

Studies the money was for Research payments · program years 2019–2025

A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging $71,817 2 payments
Assessment of Combined CCM and ICD Device in HFrEF (INTEGRA-D) $71,605 2 payments
A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging in Patients With Chronic Heart Failure With Preserved Ejection Fraction $8,806 1 payment
BAY59-7939 2.5mg reduction atherothrombotic events vs. ASA $3,779 4 payments
Longevity Study $1,360 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.